BUSINESS WIRE

Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Loading media player...
Patient advocates comment on FDA approval of Soliris(R) (eculizumab) for aHUS

Embed